SIGA — SIGA Technologies, Inc. · 2026-09-07 · Verdict: WATCH · Conviction 3
Price $3.29 (screen row, universe_under2b.csv refreshed 2026-09-07; no live quotes available) · Mkt cap $236.4M on 71.84M shares · EV $118.8M · EV/EBIT 5.0x on CY2025 EBIT of $23.7M · FCF yield 18.4% on CY2025 CFO of $43.5M · Net cash $117.6M · ADV $2.3M Sources read: 10-K 2026-03-10 (Items 1, 1A, 7), 10-Q 2026-08-06, DEF 14A 2026-04-28, 8-Ks of 2026-03-10, 03-26, 05-07, 06-10, 08-06, Form 4s (12 of 13), Q2 2026 call transcript.
1. What the business actually does
SIGA sells one product, TPOXX (tecovirimat), an FDA-approved smallpox antiviral in oral and IV form, almost entirely to governments for stockpiling. It has supplied the US Strategic National Stockpile since 2013, owns no plants and employs 49 people (10-K 2025, Item 1). Since 2018 nearly all revenue has come from one instrument, the 19C BARDA contract, worth roughly $630 million, of which $545.2 million sits in options now all exercised (10-Q).
2. Why it might be mispriced, and the honest answer
The screen's DEBT DATA MISSING warning resolves favourably: at June 30 2026 cash was $117.6 million against $10.4 million of total liabilities and no debt, with $41.1 million of inventory on top (Q2 balance sheet, 8-K 2026-08-06). That is not an edge, because everyone can see the cash. The stock sits 60% below its 52-week high for reasons SIGA discloses itself: the Q2 IV deliveries "completed the last procurement order under the 19C contract" (8-K 2026-08-06), the only unexercised options are $5.6 million of supportive work "that we currently do not expect to be required" (10-Q), no successor contract has been awarded, and the European Commission adopted the CHMP opinion stripping the mpox indication in May 2026 (10-Q). No misunderstood segment and no forced seller is visible in the filings. The nearest thing to an edge is that the market may be reading a delay as a cancellation while BARDA keeps funding SIGA's development work, $3.1 million of R&D revenue in Q2 plus $27.5 million added during 2025 (Item 1). That is a policy bet, not an analytical edge, so the verdict is capped at WATCH.
3. Unit economics and growth
Product revenue was $133.3 million in 2024, $88.0 million in 2025 and $41.4 million in the first half of 2026, with gross margin falling on mix from 76.5% to 66.2% to 50.5% because IV TPOXX carries a stated margin below 40% (Item 1) and was $25.6 million of the half (10-K Item 7; 10-Q). Operating income went $70.0 million, $23.7 million, then $8.6 million (8-K 2026-08-06), against a fixed base near $36 million a year of SG&A plus R&D.
The most important number is in the tax note. The half-year effective rate of 16.6% differs from statutory "primarily as a result of currently forecasted losses for the full year" (10-Q). Management's own accrual therefore embeds a full-year 2026 pre-tax loss against $10.8 million already booked, implying a larger second-half loss.
4. Balance sheet and capital allocation
Cash fell from $155.0 million to $117.6 million in the half, $43.3 million of it the April special dividend; operations contributed $6.5 million against $70.1 million a year earlier (10-Q). SIGA has paid three consecutive $0.60 specials totalling $129 million and runs no buyback (10-K Item 7). The proxy asks for 6,500,000 more plan shares, 9.1% of the count; MacAndrews and Forbes owns 33.68% and John Latane Lewis IV 7.35%, against 2.73% for officers and directors (DEF 14A). There were zero open-market insider purchases and zero sales in twelve months; all 47 Form 4 rows are grants and vesting.
5. Management: said versus did
Guidance was met. May guidance of $13 million of oral TPOXX internationally in Q2 and $26 million of IV by end-Q3 (8-K 2026-05-07) arrived as $13 million oral and $24 million IV in Q2, the IV a quarter early and slightly light. Against that, the PEP submission slipped from an original 2024 target to "the first half of 2027" (Item 1A; 10-Q). The CEO conceded "progress toward a new contract has been slower than in the past", blaming change within HHS, the transfer of the contract from BARDA to SNS, and open leadership posts (Q2 call, CEO).
6. Valuation
Base (40%): a smaller, later US contract in 2027. $70 million of US product at 70% margin plus $20 million international at 65% leaves $26 million of EBIT over the $36 million cost base, $20 million after tax; ten times plus $93 million of remaining cash is $4.09. Bear (40%): no award through 2028, international at $15 to $20 million, dividend stopped, cash down to $60 million and half the inventory written off, a risk SIGA names itself (Item 1A, "losses due to potential inventory write-offs"). About $1.45. Bull (20%): an award at 19C scale in 2027, international at $40 million with Hikma MENA contributing, PEP approved. EBIT near $44 million, twelve times plus cash, about $7.14, roughly 2024's earnings power. Probability-weighted value is $3.65 against $3.29, about 11% upside, not enough for a single-product, single-customer company. Reverse DCF: the $118.8 million enterprise value, capitalised at 12% with no growth, implies about $14 million a year of after-tax free cash flow in perpetuity, roughly $18 million of EBIT, three quarters of 2025's and a quarter of 2024's. The price is not discounting zero. It is discounting a permanently smaller SIGA, and is already ahead of management's own 2026 forecast.
7. Catalysts and timeline
A new US procurement award, timing unknown and the only thing that matters. Confirmation of the Assistant Secretary for Preparedness and Response, which the CEO flagged as gating, an international order targeted for delivery by March 2027, and paediatric Phase I data by year-end (Q2 call). Q3 results in November, the first quarter with no 19C order to deliver. PEP submission in the first half of 2027 (10-Q).
8. Pre-registered kill criteria
- No new US procurement contract or order announced by the Q4 2026 results, due March 2027. The stub is an option on one event, and it decays.
- An inventory write-down above $10 million against the $41.1 million June 30 balance, turning the hidden asset into a dead one.
- Cash below $90 million at any quarter end with no US award, meaning the cost base is eating what supports the price.
- The 2027 dividend cut while the contract is unawarded, or another $43 million paid out with no contract in hand.
9. Verdict and one-paragraph summary
WATCH, conviction 3. SIGA holds $117.6 million of cash, half its market value, against $10.4 million of total liabilities and no debt, so the stub costs about $119 million for a franchise that earned $70.0 million of operating income in 2024 and $23.7 million in 2025. The reason it is cheap is not hidden: the last order under the eight-year BARDA contract was delivered in Q2 2026, no successor award exists, and management's own half-year tax provision quietly forecasts a full-year loss. The company keeps executing, meeting delivery guidance, licensing MENA to Hikma and winning a multi-year Asia Pacific contract, and BARDA keeps funding development, so the relationship looks delayed rather than over. But the case rests on one procurement decision inside an HHS the CEO calls slow and short of leadership, and a probability-weighted $3.65 against $3.29 does not pay for that binary.
Research for discussion, not investment advice. Positions and sizing are the reader's decision.